Astellas secured an exclusive option to license global rights to an AviadoBio gene therapy in development as a one-time treatment for a certain type of frontotemporal dementia. A Phase 1/2 test of the AviadoBio gene therapy is ongoing.
The post Another Astellas Gene Therapy Deal, This Time $50M for Option on AviadoBio Dementia Program appeared first on MedCity News.
